Do analysts prefer IZTC or TNYA?

Tenaya Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 950.70%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tenaya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has stronger valuation and earnings, IZTC or TNYA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A Tenaya Therapeutics N/A N/A -$90.60M -$0.53 N/A

Is IZTC or TNYA more profitable?

Invizyne Technologies' return on equity of 0.00% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A Tenaya Therapeutics N/A -83.75% -66.53%

Do analysts prefer LUCD or IZTC?

Lucid Diagnostics presently has a consensus target price of $4.19, suggesting a potential upside of 776.05%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Lucid Diagnostics is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lucid Diagnostics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, LUCD or IZTC?

Invizyne Technologies has lower revenue, but higher earnings than Lucid Diagnostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lucid Diagnostics $4.71M 20.63 -$58.01M -$0.47 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is LUCD or IZTC more profitable?

Invizyne Technologies has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%. Company Net Margins Return on Equity Return on Assets Lucid Diagnostics -959.76% N/A -119.57% Invizyne Technologies N/A N/A N/A

Do analysts prefer IZTC or SPRB?

Spruce Biosciences has a consensus target price of $158.33, indicating a potential upside of 299.33%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Spruce Biosciences 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.77

Which has stronger earnings and valuation, IZTC or SPRB?

Invizyne Technologies has higher earnings, but lower revenue than Spruce Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A Spruce Biosciences $4.91M 23.18 -$38.97M -$39.78 N/A

Is IZTC or SPRB more profitable?

Invizyne Technologies' return on equity of 0.00% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A Spruce Biosciences N/A -123.53% -90.35%

Do analysts prefer CLLS or IZTC?

Cellectis currently has a consensus price target of $5.46, indicating a potential upside of 425.00%. Given Cellectis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cellectis is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectis 2 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.29 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, CLLS or IZTC?

Invizyne Technologies has lower revenue, but higher earnings than Cellectis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectis $79.59M 1.31 -$67.59M -$0.65 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Which has preferable earnings & valuation, TNXP or IZTC?

Invizyne Technologies has lower revenue, but higher earnings than Tonix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tonix Pharmaceuticals $13.11M 7.90 -$124.02M -$12.94 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Invizyne Technologies (IZTC) Competitors

$4.00 -0.60 (-13.04%)

As of 10/15/2026

Compare

IZTC vs. TNYA, LUCD, SPRB, CLLS, and TNXP

Should you buy Invizyne Technologies stock or one of its competitors? Invizyne Technologies's main competitors and comparable companies include Tenaya Therapeutics (TNYA), Lucid Diagnostics (LUCD), Spruce Biosciences (SPRB), Cellectis (CLLS), and Tonix Pharmaceuticals (TNXP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Invizyne Technologies compare to Tenaya Therapeutics?

Invizyne Technologies (NASDAQ:IZTC) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

90.5% of Tenaya Therapeutics shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Tenaya Therapeutics had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Tenaya Therapeutics and 0 mentions for Invizyne Technologies. Tenaya Therapeutics' average media sentiment score of 0.54 beat Invizyne Technologies' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
Tenaya Therapeutics	Positive

Tenaya Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 950.70%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Invizyne Technologies' return on equity of 0.00% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Tenaya Therapeutics	N/A	-83.75%	-66.53%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A

Summary

Tenaya Therapeutics beats Invizyne Technologies on 8 of the 10 factors compared between the two stocks.

How does Invizyne Technologies compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Lucid Diagnostics presently has a consensus target price of $4.19, suggesting a potential upside of 776.05%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Lucid Diagnostics is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Invizyne Technologies has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-959.76%	N/A	-119.57%
Invizyne Technologies	N/A	N/A	N/A

74.0% of Lucid Diagnostics shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Invizyne Technologies has lower revenue, but higher earnings than Lucid Diagnostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	20.63	-$58.01M	-$0.47	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

In the previous week, Lucid Diagnostics had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Lucid Diagnostics and 0 mentions for Invizyne Technologies. Lucid Diagnostics' average media sentiment score of 1.13 beat Invizyne Technologies' score of 0.00 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Lucid Diagnostics	Positive
Invizyne Technologies	Neutral

Summary

Lucid Diagnostics beats Invizyne Technologies on 8 of the 10 factors compared between the two stocks.

How does Invizyne Technologies compare to Spruce Biosciences?

Invizyne Technologies (NASDAQ:IZTC) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Spruce Biosciences had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for Spruce Biosciences and 0 mentions for Invizyne Technologies. Spruce Biosciences' average media sentiment score of 1.04 beat Invizyne Technologies' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
Spruce Biosciences	Positive

Spruce Biosciences has a consensus target price of $158.33, indicating a potential upside of 299.33%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

91.7% of Spruce Biosciences shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Invizyne Technologies has higher earnings, but lower revenue than Spruce Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Spruce Biosciences	$4.91M	23.18	-$38.97M	-$39.78	N/A

Invizyne Technologies' return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Spruce Biosciences	N/A	-123.53%	-90.35%

Summary

Spruce Biosciences beats Invizyne Technologies on 8 of the 10 factors compared between the two stocks.

How does Invizyne Technologies compare to Cellectis?

Cellectis (NASDAQ:CLLS) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

63.9% of Cellectis shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cellectis currently has a consensus price target of $5.46, indicating a potential upside of 425.00%. Given Cellectis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cellectis is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.29
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Cellectis had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for Cellectis and 0 mentions for Invizyne Technologies. Cellectis' average media sentiment score of 0.53 beat Invizyne Technologies' score of 0.00 indicating that Cellectis is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectis	Positive
Invizyne Technologies	Neutral

Invizyne Technologies has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. Invizyne Technologies' return on equity of 0.00% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Invizyne Technologies	N/A	N/A	N/A

Invizyne Technologies has lower revenue, but higher earnings than Cellectis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	1.31	-$67.59M	-$0.65	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Summary

Cellectis beats Invizyne Technologies on 9 of the 12 factors compared between the two stocks.

How does Invizyne Technologies compare to Tonix Pharmaceuticals?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Invizyne Technologies has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. Invizyne Technologies' return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%
Invizyne Technologies	N/A	N/A	N/A

Tonix Pharmaceuticals currently has a consensus target price of $24.50, suggesting a potential upside of 305.63%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Tonix Pharmaceuticals is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for Tonix Pharmaceuticals and 0 mentions for Invizyne Technologies. Tonix Pharmaceuticals' average media sentiment score of 0.63 beat Invizyne Technologies' score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Tonix Pharmaceuticals	Positive
Invizyne Technologies	Neutral

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Invizyne Technologies has lower revenue, but higher earnings than Tonix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	7.90	-$124.02M	-$12.94	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Summary

Tonix Pharmaceuticals beats Invizyne Technologies on 8 of the 11 factors compared between the two stocks.

Get Invizyne Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IZTC vs. The Competition

Export

Metric	Invizyne Technologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$25.01M	$3.97B	$7.44B	$12.94B
Dividend Yield	N/A	3.64%	2.50%	27.63%
P/E Ratio	N/A	9.02	195.25	18.74
Price / Sales	N/A	1,172.40	567.96	76.61
Price / Cash	N/A	122.10	76.54	51.88
Price / Book	N/A	15.94	10.29	5.85
Net Income	N/A	-$22.69M	$3.50B	$380.67M
7 Day Performance	-23.81%	-8.66%	-5.39%	-5.00%
1 Month Performance	-35.06%	-15.39%	-9.57%	-7.94%
1 Year Performance	-68.25%	1.51%	0.83%	-5.63%

Invizyne Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IZTC Invizyne Technologies	N/A	$4.00 -13.0%	N/A	-68.7%	$25.01M	N/A	N/A	29
TNYA Tenaya Therapeutics	2.4909 of 5 stars	$0.58 +6.6%	$4.00 +589.3%	-79.5%	$130.12M	N/A	N/A	70
LUCD Lucid Diagnostics	2.2065 of 5 stars	$0.64 -1.9%	$4.19 +556.3%	-61.1%	$129.67M	$4.71M	N/A	82	Positive News
SPRB Spruce Biosciences	3.3036 of 5 stars	$44.05 -3.3%	$158.33 +259.4%	-74.7%	$126.60M	$4.91M	N/A	8	Positive News
CLLS Cellectis	3.5702 of 5 stars	$1.26 +0.8%	$5.46 +333.3%	-77.0%	$126.43M	$79.59M	N/A	229

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IZTC) was last updated on 10/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Invizyne Technologies (IZTC) Competitors

IZTC vs. TNYA, LUCD, SPRB, CLLS, and TNXP

How does Invizyne Technologies compare to Tenaya Therapeutics?

Summary

How does Invizyne Technologies compare to Lucid Diagnostics?

Summary

How does Invizyne Technologies compare to Spruce Biosciences?

Summary

How does Invizyne Technologies compare to Cellectis?

Summary

How does Invizyne Technologies compare to Tonix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IZTC vs. The Competition

Invizyne Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Invizyne Technologies (IZTC) Competitors

IZTC vs. TNYA, LUCD, SPRB, CLLS, and TNXP

How does Invizyne Technologies compare to Tenaya Therapeutics?

Do institutionals and insiders have more ownership in IZTC or TNYA?

Does the media favor IZTC or TNYA?

Do analysts prefer IZTC or TNYA?

Is IZTC or TNYA more profitable?

Which has stronger valuation and earnings, IZTC or TNYA?

Summary

How does Invizyne Technologies compare to Lucid Diagnostics?

Do analysts prefer LUCD or IZTC?

Is LUCD or IZTC more profitable?

Do insiders and institutionals hold more shares of LUCD or IZTC?

Which has better earnings and valuation, LUCD or IZTC?

Does the media prefer LUCD or IZTC?

Summary

How does Invizyne Technologies compare to Spruce Biosciences?

Does the media prefer IZTC or SPRB?

Do analysts prefer IZTC or SPRB?

Do insiders and institutionals have more ownership in IZTC or SPRB?

Which has stronger earnings and valuation, IZTC or SPRB?

Is IZTC or SPRB more profitable?

Summary

How does Invizyne Technologies compare to Cellectis?

Do institutionals and insiders have more ownership in CLLS or IZTC?

Do analysts prefer CLLS or IZTC?

Does the media favor CLLS or IZTC?

Is CLLS or IZTC more profitable?

Which has preferable valuation and earnings, CLLS or IZTC?

Summary

How does Invizyne Technologies compare to Tonix Pharmaceuticals?

Is TNXP or IZTC more profitable?

Do analysts recommend TNXP or IZTC?

Does the media refer more to TNXP or IZTC?

Do institutionals & insiders have more ownership in TNXP or IZTC?

Which has preferable earnings & valuation, TNXP or IZTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IZTC vs. The Competition

Invizyne Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools